hotspot -WSS

hotspot

author：comprehensive 2025-09-14 14:48:52 - browse：4

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s messy supporting data did not meet the standard for approval.

After a day-long meeting that included impassioned testimony from ALS patients, the agency’s expert advisers voted 17-1 with one abstention that the case for NurOwn, a treatment from BrainStorm Cell Therapeutics, was based too heavily on convoluted clinical trial results and compelling but unreliable anecdotal evidence.

“Patients and families need hope, but providing false hope can be ethically problematic,” said panelist Lisa Lee, a bioethicist at Virginia Tech. “False hope is provided when the probability of a positive outcome is overestimated, and I think that seems to be the case here.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： What we need to know about Arena Bioworks

focus

WSS

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Takeda, Janssen join wearable maker to measure scratching

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Disappointing trial forces Pfizer to pivot on obesity medicine plans

30 years of 'Listening to Prozac'

hotspot

hotspot

hotspot

Medical records are filled with copy

Will the market for weight loss drugs really reach $100 billion?

Peter Hotez and the public health issue of online harassment

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

UnitedHealth’s Optum accused of antitrust violations in California

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA drug safety: Singulair case shows systemic surveillance flaws

Wikipedia

Woodcock on FDA’s accelerated approval and her next chapter

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Juul spent big to court Black leaders to promote its e

FDA drug safety: Singulair case shows systemic surveillance flaws

How to pay for weight loss drugs and save Medicare

Vertex non

focus

Wikipedia

hotspot

focus